-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In heart disease, atrial fibrillation seriously threatens people's life and health.
It refers to the loss of regular and orderly atrial electrical activity, replaced by fast and disorderly fibrillation waves, which is a serious disorder of atrial electrical activity.
.
Data show that there are 15-20 million people with atrial fibrillation in China.
With the aging of the population, the number of new patients is also rising, and the prevalence of atrial fibrillation in residents over the age of 35 has reached 0.
7%
.
Antiarrhythmic drugs generally refer to drugs that prevent and treat tachycardia and certain arrhythmias
.
According to the data of Minet, from 2015 to 2018, the market scale of antiarrhythmic drugs in China continued to expand, and the overall sales in 2018 reached 536 million yuan
.
However, at present, more than 10 million atrial fibrillation patients in China still face unmet treatment needs
.
Recently, there is good news that Sanofi's new anti-arrhythmic drug, Midarone Dronedarone Hydrochloride Tablets, has been launched in China for sinus rhythm patients with a history of paroxysmal or persistent atrial fibrillation (AF).
, which will bring new treatment options to the majority of atrial fibrillation patients in China
.
Dronedarone hydrochloride is a new type of antiarrhythmic drug
.
The drug was launched in the United States and Europe in 2009
.
Before Sanofi received NMPA marketing approval, dronedarone was produced and sold in China by CSPC Ouyi
.
Relevant data show that the peak sales of dronedarone in the global market exceed 400 million US dollars
.
It is understood that the efficacy of the drug has been extensively clinically verified.
Compared with the existing rhythm control drugs in China, the long-term safety is better, the incidence of adverse reactions is lower, and it is easy to use, without the need for dose titration, continuous ECG monitoring and dosage.
Adjustment, applicable to a wide range of people
.
At the same time, studies have shown (ADONIS study) that dronedarone hydrochloride tablets can maintain sinus rhythm for up to 158 days, (EURIDIS-ADONIS study joint analysis) to reduce the 1-year risk of recurrence in patients with atrial fibrillation by 25%
.
According to the industry, in the past, many patients with atrial fibrillation combined with thyroid disease in China had to go abroad to buy dronedarone at their own expense
.
The launch of dronedarone in China this time provides a blockbuster sinus rhythm maintenance drug for the clinic and brings more treatment options to patients
.
At present, Beijing, Shanghai, Guangzhou, Nanjing and other places have recently issued their first domestic prescriptions
.
In order to help patients with paroxysmal/persistent atrial fibrillation to relieve symptoms, prevent the recurrence of cardiovascular and stroke events, and improve compliance, Sanofi also launched a nationwide “Mike Heart Patient Care Program” in March 2022.
”, to provide medication and follow-up reminders, patient education and long-term medication insurance support for patients who meet the application conditions, so as to improve the quality of life of patients
.
In fact, in the field of antiarrhythmic targeted drug development, there are still some drugs that are advancing in recent years, but they are stopped halfway
.
For example, Budiodarone is another amiodarone analog with a shortened half-life
.
In the PASCAL study, Budiodarone blocked multiple ion channels and greatly reduced cardiac burden in patients with paroxysmal atrial fibrillation with pacemakers
.
Despite these encouraging preliminary results, development of Budiodarone was halted, in part due to the need for large-scale outcome trials and negative results from the ANDROMEDA and PALLAS studies
.
The research and development of new drugs is characterized by high risks and high investment.
It is not easy to develop new drugs with safety and efficacy for the majority of patients in a new field, but the exploration will not stop.
the majority of patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
It refers to the loss of regular and orderly atrial electrical activity, replaced by fast and disorderly fibrillation waves, which is a serious disorder of atrial electrical activity.
.
Data show that there are 15-20 million people with atrial fibrillation in China.
With the aging of the population, the number of new patients is also rising, and the prevalence of atrial fibrillation in residents over the age of 35 has reached 0.
7%
.
Antiarrhythmic drugs generally refer to drugs that prevent and treat tachycardia and certain arrhythmias
.
According to the data of Minet, from 2015 to 2018, the market scale of antiarrhythmic drugs in China continued to expand, and the overall sales in 2018 reached 536 million yuan
.
However, at present, more than 10 million atrial fibrillation patients in China still face unmet treatment needs
.
Recently, there is good news that Sanofi's new anti-arrhythmic drug, Midarone Dronedarone Hydrochloride Tablets, has been launched in China for sinus rhythm patients with a history of paroxysmal or persistent atrial fibrillation (AF).
, which will bring new treatment options to the majority of atrial fibrillation patients in China
.
Dronedarone hydrochloride is a new type of antiarrhythmic drug
.
The drug was launched in the United States and Europe in 2009
.
Before Sanofi received NMPA marketing approval, dronedarone was produced and sold in China by CSPC Ouyi
.
Relevant data show that the peak sales of dronedarone in the global market exceed 400 million US dollars
.
It is understood that the efficacy of the drug has been extensively clinically verified.
Compared with the existing rhythm control drugs in China, the long-term safety is better, the incidence of adverse reactions is lower, and it is easy to use, without the need for dose titration, continuous ECG monitoring and dosage.
Adjustment, applicable to a wide range of people
.
At the same time, studies have shown (ADONIS study) that dronedarone hydrochloride tablets can maintain sinus rhythm for up to 158 days, (EURIDIS-ADONIS study joint analysis) to reduce the 1-year risk of recurrence in patients with atrial fibrillation by 25%
.
According to the industry, in the past, many patients with atrial fibrillation combined with thyroid disease in China had to go abroad to buy dronedarone at their own expense
.
The launch of dronedarone in China this time provides a blockbuster sinus rhythm maintenance drug for the clinic and brings more treatment options to patients
.
At present, Beijing, Shanghai, Guangzhou, Nanjing and other places have recently issued their first domestic prescriptions
.
In order to help patients with paroxysmal/persistent atrial fibrillation to relieve symptoms, prevent the recurrence of cardiovascular and stroke events, and improve compliance, Sanofi also launched a nationwide “Mike Heart Patient Care Program” in March 2022.
”, to provide medication and follow-up reminders, patient education and long-term medication insurance support for patients who meet the application conditions, so as to improve the quality of life of patients
.
In fact, in the field of antiarrhythmic targeted drug development, there are still some drugs that are advancing in recent years, but they are stopped halfway
.
For example, Budiodarone is another amiodarone analog with a shortened half-life
.
In the PASCAL study, Budiodarone blocked multiple ion channels and greatly reduced cardiac burden in patients with paroxysmal atrial fibrillation with pacemakers
.
Despite these encouraging preliminary results, development of Budiodarone was halted, in part due to the need for large-scale outcome trials and negative results from the ANDROMEDA and PALLAS studies
.
The research and development of new drugs is characterized by high risks and high investment.
It is not easy to develop new drugs with safety and efficacy for the majority of patients in a new field, but the exploration will not stop.
the majority of patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
